Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation
Authors:
Open Access
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1689-1694
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant PatientsTransplantation and Cellular Therapy, 2017
- Occult hepatitis B infection reactivation after ruxolitinib therapyDigestive and Liver Disease, 2017
- Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsAmerican Journal of Hematology, 2016
- Klebsiella pneumoniae primary liver abscess associated with ruxolitinibAnnals of Hematology, 2016
- B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6Journal of Experimental Medicine, 2016
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015
- Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia EffectPLOS ONE, 2014
- Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host diseaseBlood, 2009
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2006
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005